Key result
In a meta-analysis of 55,580 participants, aspirin was associated with a 32% reduction in the risk of a first MI and a 15% reduction in all important vascular events for primary prevention.
Why the study?
Does aspirin reduce the risk of first MI and vascular events in individuals without prior cardiovascular disease?
Population
55,580 randomized participants from 5 trials for primary prevention of cardiovascular disease.
Comparison
Aspirin vs Control/Placebo (depending on the specific trial)
Design
Meta-analysis, Randomized, Double-blind
Authors
Loading...
Supports aspirin for primary prevention at ≥10% 10-year risk; reinforces meta-analytic evidence for first MI and vascular event reduction.
Meta-Analysis (n=55,580)
Yes
Does aspirin reduce the risk of first MI and vascular events in individuals without prior cardiovascular disease?
Effect estimate: 32% reduction
Aspirin significantly reduces the risk of a first MI and all important vascular events in primary prevention, supporting its use in individuals with a 10-year coronary event risk of ≥10%.
Eidelman et al. (2003) conducted a meta-analysis in Primary prevention of cardiovascular disease (n=55,580). Aspirin vs. Placebo or control was evaluated on First myocardial infarction (32% reduction). In a meta-analysis of 55,580 participants, aspirin was associated with a 32% reduction in the risk of a first MI and a 15% reduction in all important vascular events for primary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: